Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination

References

• Gaibani P, Ambretti S, Berlingeri A, Gelsomino F, Bielli A, Landini MP, et al. Rapid increase of carbapenemase-producing Klebsiella pneumoniae strains in a large Italian hospital: surveillance period 1 March–30 September 2010. Euro Surveill. 2011;16.
   Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20:440–58.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36.
   PubMed Web of Science ®Google Scholar
• Aktas Z, Kayacan CB, Schneider I, Can B, Midilli K, Bauernfeind A. Carbapenem-hydrolyzing oxacillinase, OXA-48, persists in Klebsiella pneumoniae in Istanbul, Turkey. Chemotherapy. 2008;54:101–6.
   PubMed Web of Science ®Google Scholar
• Gulmez D, Woodford N, Palepou MF, Mushtaq S, Metan G, Yakupogullari Y, et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents. 2008;31:523–6.
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65:1119–25.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791–8.
   PubMed Web of Science ®Google Scholar
• Albur M, Noel A, Bowker K, MacGowan A. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56:3441–3.
   PubMed Web of Science ®Google Scholar
• Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18:439–48.
   PubMed Web of Science ®Google Scholar
• CLSI CaLSI. Performance standards for antimicrobial susceptibility testing. M100-S21: M100-S21. Wayne, PA: CLSI CaLSI; 2011.
   Google Scholar
• CLSI CaLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th edn. M07-A9: M07-A9, Wayne, PA: CLSI CaLSI; 2012.
   Google Scholar
• EUCAST ECoAST. Breakpoint tables for interpretation of MICs and zone diameters, Version 3.1; 2013.
   Google Scholar
• Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2011;66:946–7.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother. 2011;55:5134–42.
   PubMed Web of Science ®Google Scholar
• CLSI CaLSI. Methods for determining bacterial activity of antimicrobial agents; approved guideline: M26A. Clinical and Laboratory Standards Institute; 1999.
   Google Scholar
• Petersen PJ, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagn Microbiol Infect Dis. 2007;59:347–9.
   PubMed Web of Science ®Google Scholar
• Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011;37:244–7.
   PubMed Web of Science ®Google Scholar
• Miller TA, Schaefer FW3rd. Characterization of a single dose methylprednisolone acetate immune suppression model using Cryptosporidium muris and Cryptosporidium parvum. Vet Parasitol. 2006;141:66–83.
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents. 2009;33:33–9.
   PubMed Web of Science ®Google Scholar
• Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2002;46:1946–52.
   PubMed Web of Science ®Google Scholar
• Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C, et al. Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis. 2005;40:e84–6.
   Google Scholar
• Maherault AC, Nordmann P, Therby A, Pangon B. Efficacy of imipenem for the treatment of bacteremia due to an OXA-48-producing Klebsiella pneumoniae isolate. Clin Infect Dis. 2012;54:577–8.
   PubMed Web of Science ®Google Scholar
• Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy. 2007;27:1052–7.
   PubMed Web of Science ®Google Scholar
• Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2008;62:1311–8.
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother. 2006;57:573–6.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–50.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013;11:159–77.
   PubMed Web of Science ®Google Scholar
• Navarro-San Francisco C, Mora-Rillo M, Romero-Gomez MP, Moreno-Ramos F, Rico-Nieto A, Ruiz-Carrascoso G, et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013;19:E72–9.
   PubMed Web of Science ®Google Scholar